These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2680009)

  • 41. The use of THA for Alzheimer's disease.
    Brodaty H
    Med J Aust; 1990 Jun; 152(11):614. PubMed ID: 2348794
    [No Abstract]   [Full Text] [Related]  

  • 42. Tacrine in relation to amino acid transmitters in Alzheimer's disease.
    Bowen DM; Steele JE; Lowe SL; Palmer AM
    Adv Neurol; 1990; 51():91-6. PubMed ID: 1967197
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease.
    Molloy DW; Guyatt GH; Wilson DB; Duke R; Rees L; Singer J
    CMAJ; 1991 Jan; 144(1):29-34. PubMed ID: 1984813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease.
    Heyman A; Schmechel D; Wilkinson W; Rogers H; Krishnan R; Holloway D; Schultz K; Gwyther L; Peoples R; Utley C
    J Neural Transm Suppl; 1987; 24():279-86. PubMed ID: 3479525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.
    Wilcock GK; Surmon DJ; Scott M; Boyle M; Mulligan K; Neubauer KA; O'Neill D; Royston VH
    Age Ageing; 1993 Sep; 22(5):316-24. PubMed ID: 8237620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients.
    Alhainen K; Helkala EL; Riekkinen P
    Dementia; 1993; 4(1):54-8. PubMed ID: 8358507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Drug therapy of Alzheimer's disease. General concepts on nootropic drugs].
    Otomo E
    Nihon Rinsho; 1988 Jul; 46(7):1569-74. PubMed ID: 3221464
    [No Abstract]   [Full Text] [Related]  

  • 48. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature.
    Arrieta JL; Artalejo FR
    Age Ageing; 1998 Mar; 27(2):161-79. PubMed ID: 16296676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cholinergic treatment in Alzheimer's disease: encouraging results.
    Lancet; 1987 Jan; 1(8525):139-41. PubMed ID: 2879974
    [No Abstract]   [Full Text] [Related]  

  • 50. [Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS].
    Fredj G; Dietlin F; Barbier G; Jasmin C; Bonhomme L; Esctein S; Misset JL; Meyer P; Kalifa D; Beugre T
    Therapie; 1992; 47(3):245-7. PubMed ID: 1295125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Double blind study of lecithin in patients with Alzheimer's disease.
    Fisman M; Merskey H; Helmes E; McCready J; Colhoun EH; Rylett BJ
    Can J Psychiatry; 1981 Oct; 26(6):426-8. PubMed ID: 7028239
    [No Abstract]   [Full Text] [Related]  

  • 52. Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease.
    Minthon L; Edvinsson L; Gustafson L
    Dementia; 1994; 5(6):295-301. PubMed ID: 7866482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Somatostatin and cognitive functions in Alzheimer's disease--the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine.
    Alhainen K; Sirviö J; Helkala EL; Reinikainen K; Riekkinen P
    Neurosci Lett; 1991 Sep; 130(1):46-8. PubMed ID: 1684233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tetrahydroaminoacridine or THA. Disputed value in Alzheimer's type dementia].
    Chatellier G
    Rev Prat; 1993 Mar; 43(6):725-8. PubMed ID: 8341950
    [No Abstract]   [Full Text] [Related]  

  • 55. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spouses' assessments of Alzheimer patients' response to THA and lecithin.
    Fitten LJ; Ganzell S
    Am J Psychiatry; 1992 Apr; 149(4):575. PubMed ID: 1554054
    [No Abstract]   [Full Text] [Related]  

  • 58. Tetrahydroaminoacridine in HIV infections. The THA Study Group.
    Fredj G; Dietlin F; Fredj D; Schwarzenberg L; Jasmin C; Meyer P; Misset JL
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):408-10. PubMed ID: 2793276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
    Schneider LS; Farlow MR; Henderson VW; Pogoda JM
    Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.